News

Proto Labs Unveils Axtra3D HPS Technology for Enhanced Productivity

Proto Labs Unveils Axtra3D HPS Technology for Enhanced Productivity

Proto Labs introduces Axtra3D Hybrid PhotoSynthesis (HPS)

Proto Labs, Inc. has taken a meaningful step forward in 3D printing with the launch of its Axtra3D Hybrid PhotoSynthesis (HPS) technology. The addition broadens an already capable platform and positions the company to better serve customers whose needs are moving from one-off prototypes to consistent, production-grade parts. HPS signals Proto Labs’ focus on more advanced, end-to-end manufacturing solutions and on expanding into applications that demand both speed and precision.

How HPS raises the bar in 3D printing

Axtra3D HPS pairs precision lasers with a digital light processing system to work in concert during the build. By combining these light sources, the process captures both the internal and external features of a part at the same time, rather than forcing a trade-off between surface detail and structural fidelity. That dual capture helps address common limits of traditional approaches and supports tighter tolerances, smoother surfaces, and more repeatable outcomes—print after print.

What does that mean in practice? HPS is built for production-grade parts when high throughput and consistent quality matter. It can also deliver cosmetic prototypes with glass-like surface finishes that are suited to demanding inspection, testing, and validation. In short: parts that need to look right and hold up under scrutiny.

Diverse HPS material offerings

Proto Labs currently supports two materials for HPS: Tough Black (Loctite Henkel 3843) and Ceramic-filled (BASF 3280). Tough Black is a strong, impact-resistant resin well suited to engineering uses where durability is a priority. The Ceramic-filled option emphasizes rigidity and is commonly used for tooling and molding applications that call for a stiff, stable material. Together, these resins broaden the company’s advanced photopolymer catalog and give customers more flexibility in matching material behavior to the job at hand.

Q2 results point to momentum

In its most recent second-quarter report, Proto Labs posted revenue of $126 million, a 3.3% increase year over year, in line with market expectations. The company also recorded earnings of 18 cents per share, a notable improvement from a loss in the same period last year. The combination—higher sales and a return to positive earnings—speaks to steady execution and a healthier operating profile.

Stock performance and comparison

Over the last year, Proto Labs’ shares have edged up 0.4% while the broader industry has declined. It’s a modest gain, but it underscores resilience in a choppy market and suggests the company’s focus on higher-value applications is resonating with investors.

Industry rankings and the competitive landscape

Proto Labs currently carries a Zacks Rank of #2 (Buy), reflecting a favorable outlook within Industrial Products. The company sits alongside peers with similarly strong rankings, including Crane Company (CR), Flowserve Corporation (FLS), and Cintas Corporation (CTAS). Each shows solid earnings potential in today’s environment.

Crane Company’s estimated earnings for 2024 stand at $5.07 per share, and the consensus estimate has risen by 6% recently—an indication of growing confidence. Flowserve and Cintas also post encouraging figures and meaningful annual growth indicators, underscoring a competitive but healthy sector.

Bottom line

Proto Labs’ Axtra3D HPS technology is a timely addition to the 3D printing toolkit. With a hybrid light approach, a focused material set, and improving financial results, the company is set up to serve more production-ready applications without losing sight of surface finish and detail. That balance—speed, quality, and choice—will likely matter more as customers demand parts that move cleanly from prototype to production.

Frequently Asked Questions

What is Axtra3D HPS technology, in simple terms?

It’s Proto Labs’ new 3D printing process that uses both precision lasers and digital light processing at the same time. By doing so, it captures fine exterior detail and internal features in one pass, supporting higher quality and consistency.

What kinds of parts is HPS best suited for?

HPS targets two sweet spots: production-grade parts that need high throughput and reliable quality, and cosmetic prototypes that call for a glass-like surface finish suitable for testing and validation.

Which HPS materials are available, and when would I use them?

Two resins are currently offered: Tough Black (Loctite Henkel 3843), a strong, impact-resistant choice for engineering applications, and Ceramic-filled (BASF 3280), a rigid material commonly used in tooling and molding. Choose based on whether you need toughness or stiffness.

How did Proto Labs perform financially in the second quarter?

The company reported $126 million in revenue, up 3.3% year over year, and earnings of $0.18 per share. Results were in line with market expectations and improved from a loss in the prior-year quarter.

What’s Proto Labs’ current standing in the market?

Proto Labs holds a Zacks Rank of #2 (Buy). Over the past year, its shares are up 0.4%, contrasting with a decline across the broader industry—an outcome that points to relative strength in a volatile backdrop.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 99

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 227

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 211

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 155

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 138

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 136

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 193

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

CNX Resources Reveals Third Quarter Results and Upcoming Call

Updated Category News Views 36

CNX Resources Corporation Financial Update CNX Resources Corporation (NYSE: CNX) is gearing up to announce its financial outcomes for the third quarter of 2024. This announcement is scheduled for 6:45 a.m. Eastern Time on a Thursday morning toward the end of October. During this time, CNX will also share essential materials, including remarks prepared for the quarter,...

Continue Reading
MBZUAI Enhances Research Collaboration with École Polytechnique

Updated Category News Views 183

Strengthening Research Cooperation Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has officially expanded its strategic partnership with École Polytechnique, aiming for a more profound collaboration in artificial intelligence (AI) research. This new Collaborative Research Agreement is a significant step towards enhancing research capabilities in both...

Continue Reading
Projected Growth of Marine Collagen: Key Insights and Trends

Updated Category News Views 152

The Growing Marine Collagen Market The marine collagen market is set to experience significant growth in the coming years. As consumer awareness around health and beauty continues to rise, we see a shift in preference towards marine collagen, thanks to its impressive bioavailability and sustainable sourcing methods. Recent analyses reveal that this sector is predicted to...

Continue Reading
BioLife Solutions Prepares for Q1 2025 Financial Disclosure

Updated Category News Views 144

Exciting Financial Insights Awaiting from BioLife Solutions BioLife Solutions, Inc. (NASDAQ: BLFS) has announced that it will disclose its first quarter 2025 financial results, marking an important update for investors and stakeholders alike. This revelation is set to occur after the market closes, creating anticipation among those closely monitoring the company’s...

Continue Reading
FuboTV Achieves Record Subscriber Growth in North America

Updated Category News Views 174

FuboTV Reports Unprecedented Subscriber Growth FuboTV (NYSE: FUBO) has recently made headlines as it recorded the highest-ever growth in its North American subscriber base. This achievement highlights the company’s potential in the competitive streaming industry. The stock saw a notable increase on the day the company announced its earnings for the third quarter....

Continue Reading